Citius Oncology Stock Soars 15.41% After Volatility

On June 25, 2025, Citius Oncology's stock surged by 15.41% in pre-market trading, marking a significant rebound after recent volatility.

Citius Oncology, Inc. is anticipated to achieve breakeven in the near future, making it an opportune time for analysis. The company's average price target is set at $6.00, which is 125.56% higher than the current price, with a consensus rating of "Buy".

On June 23, 2025, Citius Oncology experienced a notable decline of 16.35% in pre-market trading, reflecting the broader volatility in the biotech sector. This drop was attributed to market fluctuations and investor sentiment.

Analysts have provided a consensus rating of "Buy" for Citius Oncology, with a price target of $6.00, indicating a potential upside of 140.00%. This positive outlook is supported by the company's strategic initiatives and market positioning.